Showing results (41-50 of 49) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2017
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 StudyChiun Hsu, Se-Hoon Lee, Samuel Ejadi, et al.American Journal of Clinical Oncology|March 18, 2016
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by ResectionPatrick M Boland, Joshua E Meyer, Adam C Berger, et al.The Journal of Clinical Investigation|June 27, 2017
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockadeMark Ayers, Jared Lunceford, Michael Nebozhyn, et al.BMC Cancer|March 6, 2019
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancerJanice M Mehnert, Andrea Varga, Marcia S Brose, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2017
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJoshua Bauml, Tanguy Y Seiwert, David G Pfister, et al.Journal of the National Cancer Institute|May 15, 2020
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040Kevin J Harrington, Denis Soulières, Christophe Le Tourneau, et al.Clinical Colorectal Cancer|September 2, 2006
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancerSteven J Cohen, R Katherine Alpaugh, Steve Gross, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q M Chow, Robert Haddad, Shilpa Gupta, et al.Lancet (London, England)|November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyBarbara Burtness, Kevin J Harrington, Richard Greil, et al.Pageof 5